PSNL vs TEM
PSNL: Personalis provides ultra-sensitive cancer genomic testing and MRD monitoring to enable personalized cancer therapy and translational research at scale. TEM: Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers.
Side-by-side fundamentals
| Metric | PSNL | TEM | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $16.06 | $69.28 | |
| Market cap | $1.7B | $9.8B | |
| Net margin FY2025, SEC XBRL | -116.7% | -19.3% | TEM higher |
| Operating margin FY2025, SEC XBRL | -126.4% | -19.9% | TEM higher |
| ROE FY2025, SEC XBRL | -31.1% | -49.9% | PSNL higher |
| ROA FY2025, SEC XBRL | -24.3% | -10.8% | TEM higher |
| Debt / equity as of 2026-09-02 | 0.00 | 3.06 | PSNL lower |
| Revenue growth (YoY) as of 2026-09-02 | -13.3% | +50.4% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +2.3% | +58.3% | TEM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 2.05 | 2.69 | |
| 1-year return as of 2026-10-08 close | +85.0% | -32.9% | PSNL higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.